Solna, Sweden, November 12, 2025 – Vivesto AB, an oncology-focused development company, will hold a live-streamed business update on Nov. 24 at 15:00 CET, focusing on the recent pipeline advancements, including the positive interim efficacy results observed in the open label, clinical pilot study with Paccal Vet in dogs with splenic hemangiosarcoma following splenectomy, as well as the positive anti-cancer effects of Cantrixil shown in several preclinical hematological cancer models.
Vivesto has made significant progress across its development pipeline during the past months and recently announced positive advancements in its Paccal Vet program, and encouraging Cantrixil preclinical results in Acute Myeloid Leukemia (AML).
On Nov. 7, Vivesto announced positive interim efficacy results from its open-label clinical pilot study of Paccal Vet (paclitaxel micellar) in dogs with Stage I–II splenic hemangiosarcoma following splenectomy. The interim data showed longer overall survival compared to surgically treated historical controls. The study included 11 of the planned 18 dogs in the interim analysis, and was conducted at eight U.S. sites. As no approved drugs exist for this condition after splenectomy, the findings represent meaningful progress toward a potential new therapeutic option. Full results are expected in H1 2026, and if confirmed, the next step will be to conduct a pivotal study to support marketing approval or potential conditional approval of Paccal Vet.
The company’s Paccal Vet dose-finding study in cats with solid tumors is progressing at three clinical sites in Washington and Oregon. The study also includes an exploratory evaluation of Paccal Vet’s anti-tumor efficacy, assessing its potential as a future cancer treatment option for cats.
On Nov. 4, Vivesto received new positive Cantrixil pre-clinical results that showed strong anti-cancer effects alone and enhanced efficacy when combined with other drugs in an in vivo model of difficult-to-treat human AML. This confirms earlier preclinical data and supports continued development for hematological cancers, particularly AML. In addition, these new findings have enabled a PCT patent application with the potential to significantly extend the duration of Cantrixil's IP protection.
“The Vivesto team is continuously striving to position Vivesto as a development company offering new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential,” said Erik Kinnman, CEO of Vivesto. “With our studies advancing for both the Paccal Vet and Cantrixil programs, it is a great opportunity for us to give an update on our work and how we see these programs progressing.”
Business update details
The business update will focus on the Paccal Vet and Cantrixil programs, including details about the recent results, the development plans going forward, medical needs and commercial potential.
Speakers will include:
External speakers:
- Henrik Rönnberg, Professor in veterinary pharmacology (DiplECVIM-CA, oncology)
- Jim Perry, Veterinary oncologist and surgeon, DVM, PhD, CEO CASTR Alliance
- Bjørn Tore Gjersten, Professor of hematology, University of Bergen
Vivesto speakers:
- Peter Zonabend, Chairman of the Board
- Erik Kinnman, CEO
- Teresa Fernandez Zafra, Chief Scientific Officer
- Johanna Röstin, Chief Regulatory Officer
- Nina Herne, Consultant, PhD, MBA
Agenda
15.00 – 15.15 — Introduction
15.15 – 15.45 — Paccal Vet
15.45 – 16.05 — Cantrixil
16.05 – 16.20 — Commercial potential
16.20 – 16.30 — Summary
16.30 — Q&A
The presentations will be followed by a Q&A session where questions can be submitted in advance via info@vivesto.com
The presentations will be held in English and can be followed via https://www.youtube.com/live/mMvLyL0w9WY and will also be available afterwards on Vivesto's website. No registration is required.